Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00886639
Other study ID # BGL O2
Secondary ID
Status Completed
Phase N/A
First received April 21, 2009
Last updated November 2, 2011
Start date December 2008
Est. completion date August 2009

Study information

Verified date November 2011
Source Klinikum Berchtesgadener Land der Schön-Kliniken
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the six-minute-walking-distance of COPD-patients with breathing oxygen in comparison to breathing normal air. Patients, who increase their walking-distance about more than 15% or 35m only because of breathing oxygen, are so-called "Oxygen Responders." The study is aimed to find attributes of Oxygen Responder and to investigate, if a patient can change the "respond" with higher performance and endurance.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date August 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chronic obstructive pulmonary disease III/IV

Exclusion Criteria:

- Severe exacerbations in the last 4 weeks prior to begin of study (definition of exacerbation: symptoms on more than 3 days with a relevant change in drug therapy (cortisone, antibiotics))

- Severe exacerbation during rehabilitation

- Cardiac insufficiency

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening


Related Conditions & MeSH terms


Intervention

Other:
6MWT with oxygen
2 liter per minute as continuous-flow
6MWT with medical air
2 liters as continuous-flow

Locations

Country Name City State
Germany Klinikum Berchtesgadener Land, Schön Kliniken Schönau am Königssee

Sponsors (2)

Lead Sponsor Collaborator
Klinikum Berchtesgadener Land der Schön-Kliniken ROX Medical, Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oxygen Response Change in oxygen response (6-minute-walking distance on oxygen minus 6-minute-walking distance on medical air) from baseline to 3 weeks day 1 and day 2; day 21 and day 22 Yes
Secondary Oxygen Partial Pressure (paO2) change in paO2 from minute 0 to minute 6 in 6-minute-walking test on oxygen/ medical air day 1: minute "0" and "6" No
Secondary Diffusion Capacity change in diffusion capacity from baseline to 3 weeks day 1 and 21 No
Secondary Lung Function change in lung function from baseline to 3 weeks day 1 and 21 No
Secondary BORG-Score change of BORG-Score from pre to post 6 minute-walking test (minute 0 and 6)on oxygen/ medical air day 1: minute 0 and minute 6 No
Secondary Oxygen Saturation Change of oxygen saturation from minute 0 to 6 in 6Minute-walking test on oxygen/ medical air day 1: minute 0 and 6 No
Secondary Oxygen Partial Pressure (paO2) change in paO2 from minute 0 to minute 6 in 6-minute-walking test on oxygen/ medical air day 21: minute 0 and minute 6 No
Secondary BORG-Score change of BORG-Score from pre to post 6 minute-walking test (minute 0 and 6)on oxygen/ medical air day 2: minute 0 and minute 6 No
Secondary BORG-Score change of BORG-Score from pre to post 6 minute-walking test (minute 0 and 6)on oxygen/ medical air day 22: minute 0 and minute 6 No
Secondary BORG-Score change of BORG-Score from pre to post 6 minute-walking test (minute 0 and 6)on oxygen/ medical air day 21: minute 0 and minute 6 No
Secondary Oxygen Partial Pressure (paO2) change in paO2 from minute 0 to minute 6 in 6-minute-walking test on oxygen/ medical air day 20: minute 0 and minute 6 No
Secondary Oxygen Partial Pressure (paO2) change in paO2 from minute 0 to minute 6 in 6-minute-walking test on oxygen/ medical air day 2: minute "0" and "6" No
Secondary Oxygen Saturation Change of oxygen saturation from minute 0 to 6 in 6Minute-walking test on oxygen/ medical air day 2: minute 0 and 6 No
Secondary Oxygen Saturation Change of oxygen saturation from minute 0 to 6 in 6Minute-walking test on oxygen/ medical air day 21: minute 0 and 6 No
Secondary Oxygen Saturation Change of oxygen saturation from minute 0 to 6 in 6Minute-walking test on oxygen/ medical air day 22: minute 0 and 6 No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy